ArticleCancers2011
Regulatory T cells in colorectal cancer: from biology to prognostic relevance.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Role of SERPINA1 in the tumor immune microenvironment of breast cancer and construction of a prognostic model.Discover oncology · 2026Article
- High IL-10 mRNA levels in regional lymph nodes of colon cancer patients indicate poor prognosis.Frontiers in immunology · 2025Article
- Parasites revive hope for cancer therapy.European journal of medical research · 2024Review
- Single-cell analysis revealed a potential role of T-cell exhaustion in colorectal cancer with liver metastasis.Journal of cellular and molecular medicine · 2024Article
- Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer.Frontiers in oncology · 2023Review
- Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.BMC immunology · 2022Article
- Article
- A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.Cancer immunology, immunotherapy : CII · 2021Article
- Article
- Article
- TGFβ and activin A in the tumor microenvironment in colorectal cancer.Gene reports · 2019Article
- Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer.Investigational new drugs · 2019Article
- Article
- Determination of a CD4Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?Cancer gene therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) were initially described as "suppressive" lymphocytes in the 1980s. However, it took almost 20 years until the concept of Treg-mediated immune control in its present form was finally established. Tregs are obligatory for self-tolerance and defects within their population lead to severe autoimmune disorders. On the other hand Tregs may promote tolerance for tumor antigens and even hamper efforts to overcome it. Intratumoral and systemic accumulation of Tregs has been observed in various types of cancer and is often linked to worse disease course and outcome. Increase of circulating Tregs, as well as their presence in mesenteric lymph nodes and tumor tissue of patients with colorectal cancer de facto suggests a strong involvement of Tregs in the antitumor control. This review will focus on the Treg biology in view of colorectal cancer, means of Treg accumulation and the controversies regarding their prognostic significance. In addition, a concise overview will be given on how Tregs and their function can be targeted in cancer patients in order to bolster an inherent immune response and/or increase the efficacy of immunotherapeutic approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.